Combination of 25-hydroxyvitamin d and antioxidants/anti-inflammatories for human nutraceuticals

A composition, nutraceutical or pharmaceutical composition selected from the group consisting of:

• Formula 1:
• 25-OH D:
• 5-25 μg, Vitamin E:
• 200-600 mg, Ascorbic acid:
• 100-1000 mg and Cryptoxanthin:
• 0.10 mg;
• Formula 2:
• 25-OH D:
• 5-25 μg;
• Vitamin E:
• 200-600 mg, Ascorbic acid:
• 100-1000 mg, Lutein 6-12 mg;
• and optionally Zeaxanthin:
• 6 mg;
• Formula 3:
• 25-OH D:
• 5-25 μg;
• Vitamin E:
• 200-600 mg, Ascorbic acid:
• 100-1000 mg, and Lycopene:
• 20 mg;
• Formula 4:
• 25-OH D:
• 5-25 μg;
• Vitamin E:
• 200-600 mg, Ascorbic acid:
• 100-1000 mg, and Astaxanthin:
• 20 mg;
• Formula #5:
• 25-OH D:
• 5-25 μg, Vitamin E:
• 200-600 mg, Ascorbic acid:
• 100-1000 mg, and Beta Carotene:
• 10 mg

A method of conferring a cardiovascular benefit comprising administering to a person in need there of an effective amount of a combination comprising:

• 25-hydroxyvitamin D3, Vitamin C, Vitamin E, and one or more carotenoids selected from the group consisting of:
• lycopene, astaxanthin, cryptoxanthin, beta-carotene, lutein, zeaxanthin and canthaxanthin;
• and the cardiovascular benefit is at least one benefit selected from the group consisting of:
• a) clearance of non-esterified fatty acids;
• b) Amelioration of plasma dyslipidemia (triglycerides, sphingomyelin, and ceramide);
• c) Amelioration of triglyceride and ceraminde accumulation in the liver, leg, breast muscle, and heart;
• d) suppression of the tissue pro-inflammatory IL-1β production and plasma IL-6 concentration;
• e) cardiac protection and enhanced cardiac function through the up-regulation of the phosphorylation of STAT-3 (signal transducer and activator of transcription 3) in the heart;
• f) suppression of the infiltration of immune cells into the heart;
• g) decreasing the incidence of ascites;
• h) decreasing the incidence of cardiovascular problems;
• i) decreasing the incidence of cardiac morbidities (dilation, pericardial effusion, rupture);
• j) decreasing the amount of irregular incidence of ECG patterns;
• k) decreasing the occurrence of arrhythmias;
• l) Ameliorating cardiac fibrosis;
• m) Ameliorating chronic systemic inflammation;
• n) Ameliorating cardiac cell apoptosis;
• and
• o) improved insulin resistance and/or blood glucose regulation.